Non-significant differences were found in the quantity of anti-MBP and anti-MOG antibodies in B cells between 77 patients with MS with active disease (17.13 ± 3.52 ng/mL and 15.64 ± 11.99 ng/mL, respectively) and 59 with stable disease (16.03 ± 7.27 ng/mL and 13.19 ± 12.97 ng/mL, respectively) (p=0.29 and p=0.31, respectively). This evidence concerns the gene MBP and myeloid sarcoma.